Researchers continue to search for imaging biomarkers that can predict who will develop Alzheimer's.
Positron emission tomography (PET) imaging of brain beta-amyloid is increasingly used in research for detecting early stages of Alzheimer's.
FDG-PET imaging was a more reliable tool than a commonly used cognitive test for monitoring Alzheimer's progression
The 2 pathologic hallmarks of Alzheimer disease are
- Extracellular beta-amyloid deposits (in senile plaques)
- Intracellular neurofibrillary tangles (paired helical filaments)
Cholinesterase inhibitors (donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®/Reminyl®)) can help manage Alzheimer's, but they do not cure or reverse the course of AD.
Memantine (Namenda®) has been approved for the treatment of moderate-severe AD.
A variety of medications are prescribed, with variable success, for psychiatric behavioral problems associated with AD and other dementia.